Step Pharmaceutical semi-annual report released the pace of transformation and innovation accelerated

Recently, Step Pharmaceuticals issued an announcement. According to the announcement, the company achieved operating income of RMB5,748 million, down 0.06% from a year earlier, and net profit attributable to shareholders of listed companies was RMB701 million, up 3.37% year-on-year.
analysis points out that step-by-step pharmaceutical net profit increased slightly, or is related to the company's ongoing transformation. Step Pharmaceuticals is in a transition period, from a sales-oriented company to a technology-based company, from traditional Chinese medicine to biopharmaceuticals, chemical drugs, medical devices, Internet medicine, and gradually from China's localization to globalization.Strengthen the strategy of "focusing on big disease species and cultivating large varieties"
Step Pharmaceuticals has continuously strengthened the long, medium and short-term strategy of "focusing on large industries and cultivating large varieties" and doing "China's Johnson and Johnson, the world's step." The company adheres to the modernization of Traditional Chinese medicine, relying on China's deep historical accumulation in the Chinese medicine industry and rich resources of medicinal herbs, science and technology as the guide, market-leading, innovation to drive the industrialization of Chinese medicine, modernization of development, play the company in theory, brand, research and development, production and sales of comprehensive advantages, further consolidate and strengthen the company's advantages in the field of cardiovascular and gynecological medicine, to achieve sustained and stable development during the reporting period.
's cerebral heart pass capsules, steady-heart particles, Danhong injection, grain red injection, compound cerebral peptide glycoside injection, compound querceptide injection, Ginkgo honey ring oral solution are mature varieties after long-term market testing, the first half of 2018 total revenue of 4.249 billion yuan.
2012, the stable particles completed a three-year clinical trial of evidence-based medical research, and its efficacy for arrhyth arrhythmics was once again confirmed. Evidence-based medical studies of cerebral palate capsules and dan red injections are also steadily under way. In addition to cerebral heart pass capsules, steady heart particles, Danhong injection, guerre red injection, compound cerebral peptide glycoside injection, compound querceptide injection, ginkgo honey ring oral solution, the company has now developed and reserved diabetes drug pass-through sugar capsules, anti-tumor medication orthopedic agent oral solution, ginseng pulse oral solution, coronary heart susception capsules, constipation capsules and anti-inflammatory capsules and other products. After the pre-trial promotion, the above-mentioned products because of the obvious efficacy and widely praised, sales also steadily increased. In the future, the company will increase the promotion of such products, cultivate the company's new growth point.
company on the basis of successful evidence-based clinical trials of steady-heart particles, continue to promote the leading product evidence-based medical re-evaluation, through clinical data to verify product efficacy, further enhance the academic connotation of the company's products and market reputation, the academic advantages of products into market advantages, promote sales growth.Increase research and development investment for the company's development to lay the foundation
step long pharmaceutical adhere to independent technological innovation and cooperative research and development, commissioned research and development and other ways of research and development model, on the basis of independent technological innovation, vigorously carry out multi-level foreign technical cooperation, with the advantages of pharmaceutical research and development enterprises, pharmaceutical well-known universities in-depth cooperation, make full use of their own research and development, market, scale and other advantages, vigorously promote international cooperation and technology introduction.For more than
years, the company has been focusing on cardiovascular, gynecological and other major disease treatment drugs research, in technology, products and personnel have accumulated significant advantages, and pay attention to the extension of the research chain, the establishment of a research based on the theory of brain-heart co-treatment, covering research, project, small trial, pilot, clinical and industrialization, extended to the drug market after evidence-based medical research complete research system. In the first half of 2018, the company filed four new patent applications and successfully obtained 6 patents, including 4 patents for inventions.
will take science and technology as the eternal driving force for development, adhere to the high, medium, low and long, medium and short for the new product research and development strategy, with academicians as the research and development consultant team, with domestic and foreign first-class research and development team has a wide range of cooperation, forming a "production generation, reserve generation, development generation, The idea of a generation" virtuous cycle research and development model, in the cardiovascular drugs, anti-tumor drugs, anti-infective drugs, gynecological drugs, digestive drugs, anti-sugar drugs and other common diseases and multi-disease treatment drugs in the development of reserves of multi-level, wide-ranging research projects.
step pharmaceutical said that after years of technology accumulation, the company has a strong technical level and research and development strength, has a good technical reserves, and set up a suitable for the company's own characteristics of independent technological innovation and multi-level foreign technical cooperation combined research and development model, for the company's future development has laid a good foundation.Accelerate the pace of transformation and innovation to improve the large health industry chain
step long pharmaceutical in the active multi-type drug research and development, and gradually improve the large health industry chain, the company in Chinese medicine, chemical medicine and biological medicine in many areas of research and development.
In the field of traditional Chinese medicine, the company, guided by the theory of brain-heart co-treatment, combines innovative groups with modern pharmaceutical technology and quality control standards, and gradually forms complementary multi-target joint drug treatment programs in a large number of long-term clinical practices to enhance the therapeutic effect; In the field of biopharmaceeutics, for tumors, cardiovascular, osteoporosis and other major diseases, long-term diseases, chronic diseases and other fields, there are currently 8 biological products (including 6 types of therapeutic biological products) are being developed, some products have entered the clinical phase II to phase III, covering tumors, osteoporosis, anemia, arthritis, cardiovascular and other areas.
In order to improve the strategic layout of the large health industry chain, the company has made a number of investments and acquisitions in channels, research and development, product aspects, including investment in the main online drug purchase platform of fast-party technology, investment in the main diagnostic reagents and medical device sales of Beijing Puen, investment in early stage functional imaging technology and image navigation tumor minimally invasive precision diagnosis and treatment technology of new Medical, joint venture to establish the main medical device research and development of Zhangzhou New Meikang.
Step Pharmaceuticals said it will continue to adhere to the "focus on major diseases, cultivate large varieties" development strategy, to develop Chinese medicine as the main line, based on the modernization of Chinese medicine, while taking into account biopharmaceuticals and chemical drugs, accelerate the company's innovation and transformation, improve core competitiveness. (China News Network)